Urologix March Stock Price Gain Propelled By BPH Systems, Disposables
This article was originally published in The Gray Sheet
Executive Summary
Increased market penetration and improved reimbursement rates for Urologix, Inc.'s Targis Cooled ThermoTherapy system for treatment of benign prostatic hyperplasia (BPH) translated into a nearly 30% stock price gain in March. The issue advanced $4.17 to close at $18.17 for the month
You may also be interested in...
Medtronic Fishes For Urology Growth, Lands TUNA BPH Device With VidaMed
Medtronic's $326 mil. acquisition of VidaMed is expected to close in January 2002, just as Medicare reimbursement for the firm's transurethral needle ablation (TUNA) system for benign prostatic hyperplasia (BPH) increases from $2,455 per procedure to $3,043
Urologix' Targis
Production of the microwave-based system for benign prostatic hyperplasia begins at Plexus Corp. under a two-year manufacturing agreement announced Oct. 24. Initial deliveries from Plexus are slated for December. Quality system deficiencies have hampered production at Colorado MEDtech under a previous arrangement (1"The Gray Sheet" Aug. 13, 2001, p. 13). Minneapolis-based Urologix continues to develop redundant, in-house manufacturing facilities for the device, approved by FDA in 1997, and expects completion by mid-2002
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.